Allogeneic Mitochondria (PN-101) Transplantation for Refractory Polymyositis or Dermatomyositis

PHASE1/PHASE2CompletedINTERVENTIONAL
Enrollment

9

Participants

Timeline

Start Date

December 15, 2021

Primary Completion Date

October 6, 2023

Study Completion Date

October 6, 2023

Conditions
PolymyositisDermatomyositis
Interventions
BIOLOGICAL

PN-101

"PN-101: Mitochondria isolated from Allogeneic Umbilical Cord-derived Mesenchymal Stem Cells.~3 or 6 subjects are enrolled in each dose group in line with the traditional 3+3 rule-based method, and the investigator intravenously administers a single-dose of the investigational product according to the planned dose."

Trial Locations (3)

03080

Seoul National University Hospital, Seoul

04401

Soonchunhyang University Seoul Hospital, Seoul

04763

Hanyang University Seoul Hospital, Seoul

Sponsors
All Listed Sponsors
lead

Paean Biotechnology Inc.

INDUSTRY